Despite evidence that KDM4C silencing or inhibition may represent an effective epigenetic therapy in BC treatment, a study conducted on 355 patients with invasive BC found that KDM4C was negatively associated with the development of a more aggressive BC histopathological type (grade II/III, ductal-type, PR-, and ER-). The gene discussed is ESR1; the disease is breast cancer.